GoodRx Holdings, Inc. (NASDAQ:GDRX) Financial Performance Analysis

• Deutsche Bank analyst George Hill sets a price target of $6 for GoodRx Holdings, Inc. (NASDAQ:GDRX), indicating a potential increase of approximately 72.91%.
• GoodRx's Q2 2025 earnings call reveals a trading range with a daily low of $3.40 and a high of $3.55, showcasing the stock's volatility.
• The company's market capitalization stands at approximately $1.22 billion, with a trading volume of 3,260,336 shares.

GoodRx Holdings, Inc. (NASDAQ:GDRX) is a company that provides consumers with information and tools to save on prescription drugs. It operates a platform that aggregates pricing data from pharmacies across the United States, helping users find the best prices for their medications. GoodRx competes with other companies in the healthcare and technology sectors, such as Amazon Pharmacy and Blink Health.

On August 11, 2025, George Hill from Deutsche Bank set a price target of $6 for GoodRx. At that time, the stock was trading at $3.47, suggesting a potential price increase of approximately 72.91%. This optimistic outlook comes shortly after GoodRx's Q2 2025 earnings call, which took place on August 7, 2025. The call featured key company figures, including CEO Wendy Barnes and CFO Christopher A. McGinnis, who discussed the company's financial performance and future strategies.

During the earnings call, GoodRx's stock was trading at $3.47, with a daily low of $3.40 and a high of $3.55. Over the past year, the stock has seen a high of $8.80 and a low of $3.30. The company's market capitalization is approximately $1.22 billion, and it has a trading volume of 3,260,336 shares. These figures highlight the stock's volatility and the potential for significant price movement.

The earnings call also included participation from Charles Rhyee of TD Cowen, Research Division, and Daniel R. Their involvement indicates a strong interest from the investment community in GoodRx's performance and strategic direction. As the company continues to navigate the competitive landscape, investors will be closely monitoring its progress and any developments that could impact its stock price.

GoodRx Holdings, Inc. (NASDAQ:GDRX) is a digital healthcare platform that provides consumers with access to affordable prescription medications. The company operates in a competitive landscape alongside peers like American Well Corporation, JFrog Ltd., Asana, Inc., nCino, Inc., and Doximity, Inc. These companies are part of the broader healthcare and technology sectors, each with unique business models and financial metrics.

In evaluating GoodRx's financial efficiency, its Return on Invested Capital (ROIC) is 3.25%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 11.82%. This results in a ROIC to WACC ratio of 0.28, indicating that GoodRx is not currently generating returns that exceed its cost of capital. This suggests that the company may need to reassess its investment strategies to improve its financial performance.

Comparatively, American Well Corporation (AMWL) has a ROIC of -64.39% and a WACC of 9.32%, resulting in a ROIC to WACC ratio of -6.91. This negative ratio highlights inefficiencies in generating returns relative to its cost of capital. Similarly, JFrog Ltd. (FROG) and Asana, Inc. (ASAN) also show negative ROIC to WACC ratios of -1.34 and -6.01, respectively, indicating challenges in achieving profitable returns.

nCino, Inc. (NCNO) presents a slightly better picture with a ROIC of -0.68% and a WACC of 7.15%, leading to a ROIC to WACC ratio of -0.10. Although still negative, nCino's ratio is closer to breaking even compared to its peers. This suggests that nCino may be on a path to improving its financial efficiency.

Doximity, Inc. (DOCS) stands out with a positive ROIC of 16.62% and a WACC of 10.42%, resulting in a ROIC to WACC ratio of 1.59. This indicates that Doximity is effectively generating returns above its cost of capital, making it the most financially efficient company among its peers. This efficiency suggests strong growth potential for Doximity in the competitive landscape.

GoodRx Holdings, Inc. (NASDAQ:GDRX) is a digital healthcare platform that provides consumers with access to affordable prescription medications. The company operates in a competitive landscape alongside peers like American Well Corporation, JFrog Ltd., Asana, Inc., nCino, Inc., and Doximity, Inc. These companies are part of the broader healthcare and technology sectors, each with unique business models and financial metrics.

In evaluating GoodRx's financial efficiency, its Return on Invested Capital (ROIC) is 3.25%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 11.82%. This results in a ROIC to WACC ratio of 0.28, indicating that GoodRx is not currently generating returns that exceed its cost of capital. This suggests that the company may need to reassess its investment strategies to improve its financial performance.

Comparatively, American Well Corporation (AMWL) has a ROIC of -64.39% and a WACC of 9.32%, resulting in a ROIC to WACC ratio of -6.91. This negative ratio highlights inefficiencies in generating returns relative to its cost of capital. Similarly, JFrog Ltd. (FROG) and Asana, Inc. (ASAN) also show negative ROIC to WACC ratios of -1.34 and -6.01, respectively, indicating challenges in achieving profitable returns.

nCino, Inc. (NCNO) presents a slightly better picture with a ROIC of -0.68% and a WACC of 7.15%, leading to a ROIC to WACC ratio of -0.10. Although still negative, nCino's ratio is closer to breaking even compared to its peers. This suggests that nCino may be on a path to improving its financial efficiency.

Doximity, Inc. (DOCS) stands out with a positive ROIC of 16.62% and a WACC of 10.42%, resulting in a ROIC to WACC ratio of 1.59. This indicates that Doximity is effectively generating returns above its cost of capital, making it the most financially efficient company among its peers. This efficiency suggests strong growth potential for Doximity in the competitive landscape.

GoodRx Holdings, Inc. (NASDAQ:GDRX) is a digital healthcare platform that provides consumers with information and tools to compare prescription drug prices and access discounts. The company operates in a competitive landscape alongside other digital health and software companies. A key metric to assess its financial performance is the comparison between Return on Invested Capital (ROIC) and Weighted Average Cost of Capital (WACC).

GoodRx's ROIC is 3.25%, while its WACC is 11.62%, resulting in a ROIC to WACC ratio of 0.28. This indicates that GoodRx is not generating returns that exceed its cost of capital. This is a critical measure as it suggests the company is not currently using its capital efficiently to create value for shareholders.

In comparison, American Well Corporation (AMWL) has a ROIC of -64.39% and a WACC of 9.28%, leading to a ROIC to WACC ratio of -6.94. Similarly, JFrog Ltd. (FROG) and Asana, Inc. (ASAN) also show negative ROIC to WACC ratios of -1.35 and -5.97, respectively. These figures highlight that these companies are also struggling to generate returns above their cost of capital.

nCino, Inc. (NCNO) presents a slightly better picture with a ROIC of -0.67% and a WACC of 7.08%, resulting in a ROIC to WACC ratio of -0.10. Although still negative, it is closer to breaking even compared to its peers. This suggests that nCino is slightly more efficient in its capital usage than others in the group.

Doximity, Inc. (DOCS) stands out with a ROIC of 16.62% and a WACC of 10.35%, achieving a ROIC to WACC ratio of 1.61. This positive ratio indicates that Doximity is effectively using its capital to generate returns well above its cost, showcasing strong capital efficiency. This makes Doximity the leader in capital utilization among its peers.

• GoodRx Holdings, Inc. (NASDAQ:GDRX) demonstrates superior capital efficiency with a ROIC of 21.60% compared to its WACC of 9.50%.
• Competitors like American Well Corporation (AMWL) and Asana, Inc. (ASAN) show negative ROIC to WACC ratios, indicating struggles in generating returns above their cost of capital.
• GoodRx's strong financial performance and efficient use of capital set it apart in the competitive digital health sector.

GoodRx Holdings, Inc. (NASDAQ:GDRX) is a company that provides a platform to help consumers find affordable prescription medications. It operates in the healthcare sector, offering price comparisons and discounts on prescription drugs. GoodRx competes with other companies in the digital health and telemedicine space, such as American Well Corporation (AMWL) and Doximity, Inc. (DOCS).

In evaluating GoodRx's financial performance, the Return on Invested Capital (ROIC) and Weighted Average Cost of Capital (WACC) are key metrics. GoodRx has an impressive ROIC of 21.60% compared to its WACC of 9.50%, resulting in a ROIC to WACC ratio of 2.27. This indicates that GoodRx is effectively using its capital to generate returns well above its cost of capital.

When comparing GoodRx to its peers, it becomes evident that GoodRx is outperforming in terms of capital efficiency. For instance, American Well Corporation (AMWL) has a negative ROIC of -65.71% and a WACC of 8.62%, leading to a ROIC to WACC ratio of -7.63. This suggests that AMWL is not generating sufficient returns to cover its cost of capital.

Similarly, JFrog Ltd. (FROG) and Asana, Inc. (ASAN) also show negative ROIC to WACC ratios of -1.30 and -8.70, respectively. These figures highlight that both companies are struggling to generate returns above their cost of capital. In contrast, Doximity, Inc. (DOCS) has a positive ROIC to WACC ratio of 1.56, but it still lags behind GoodRx's superior ratio of 2.27.

Overall, GoodRx's strong ROIC to WACC ratio underscores its ability to efficiently utilize its capital, setting it apart from its peers in the digital health sector. This financial strength positions GoodRx favorably in the competitive landscape, as it continues to deliver value to its investors.

• GoodRx Holdings, Inc. (NASDAQ:GDRX) demonstrates superior capital efficiency with a ROIC of 21.60% compared to its WACC of 9.50%.
• Competitors like American Well Corporation (AMWL) and Asana, Inc. (ASAN) show negative ROIC to WACC ratios, indicating struggles in generating returns above their cost of capital.
• GoodRx's strong financial performance and efficient use of capital set it apart in the competitive digital health sector.

GoodRx Holdings, Inc. (NASDAQ:GDRX) is a company that provides a platform to help consumers find affordable prescription medications. It operates in the healthcare sector, offering price comparisons and discounts on prescription drugs. GoodRx competes with other companies in the digital health and telemedicine space, such as American Well Corporation (AMWL) and Doximity, Inc. (DOCS).

In evaluating GoodRx's financial performance, the Return on Invested Capital (ROIC) and Weighted Average Cost of Capital (WACC) are key metrics. GoodRx has an impressive ROIC of 21.60% compared to its WACC of 9.50%, resulting in a ROIC to WACC ratio of 2.27. This indicates that GoodRx is effectively using its capital to generate returns well above its cost of capital.

When comparing GoodRx to its peers, it becomes evident that GoodRx is outperforming in terms of capital efficiency. For instance, American Well Corporation (AMWL) has a negative ROIC of -65.71% and a WACC of 8.62%, leading to a ROIC to WACC ratio of -7.63. This suggests that AMWL is not generating sufficient returns to cover its cost of capital.

Similarly, JFrog Ltd. (FROG) and Asana, Inc. (ASAN) also show negative ROIC to WACC ratios of -1.30 and -8.70, respectively. These figures highlight that both companies are struggling to generate returns above their cost of capital. In contrast, Doximity, Inc. (DOCS) has a positive ROIC to WACC ratio of 1.56, but it still lags behind GoodRx's superior ratio of 2.27.

Overall, GoodRx's strong ROIC to WACC ratio underscores its ability to efficiently utilize its capital, setting it apart from its peers in the digital health sector. This financial strength positions GoodRx favorably in the competitive landscape, as it continues to deliver value to its investors.